Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Current Deferred Revenue (2020 - 2025)

Maxcyte (MXCT) has disclosed Current Deferred Revenue for 6 consecutive years, with $5.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue fell 21.9% to $5.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.2 million, a 21.9% decrease, with the full-year FY2024 number at $5.3 million, up 3.59% from a year prior.
  • Current Deferred Revenue was $5.2 million for Q3 2025 at Maxcyte, up from $2.6 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7.3 million in Q2 2022 to a low of $2.6 million in Q2 2025.
  • A 5-year average of $5.5 million and a median of $5.7 million in 2023 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 39.31% in 2021, then plummeted 35.81% in 2023.
  • Maxcyte's Current Deferred Revenue stood at $6.7 million in 2021, then dropped by 0.5% to $6.7 million in 2022, then decreased by 24.49% to $5.1 million in 2023, then increased by 3.59% to $5.3 million in 2024, then decreased by 1.05% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Current Deferred Revenue are $5.2 million (Q3 2025), $2.6 million (Q2 2025), and $4.1 million (Q1 2025).